ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1152

A Follow-Up Evaluation of a Longstanding Telephone Peer Counseling Service for People with Systemic Lupus Erythematosus and Their Loved Ones
Abstract Number: 1153

The Influence of Companions on a Patient’s Decision to Transition to a Biosimilar: A Randomized Controlled Trial
Abstract Number: 1154

What Do Patients Know About Biosimilars and How Satisfied Are They with the Educational Process? – A Systematic Comparison Between Rheumatologists and Nurse Specialists, Including Effects of Multiswitching
Abstract Number: 1155

Pregnancy Experiences and Unmet Needs for Women of Childbearing Age with Chronic Rheumatic Disease in China
Abstract Number: 1156

Impact of Treatment Experience on Patient Preferences and Disease Burden in Psoriatic Arthritis: Results from a Rheumatology Patient Research Registry
Abstract Number: 1157

Patient Perspective on the Non Medical Switch of Originator to Its Biosimilar in Inflammatory Arthritis Using a Social Media Survey
Abstract Number: 1158

Resistance of Patients with Rheumatoid Arthritis to Changing Therapy: A 15-year Follow-up
Abstract Number: 1159

Improving Healthcare Transition Implementation: Recommendations from Young Patients with Rheumatic Conditions
Abstract Number: 1160

Evaluation of HCQ Side Effects in New and Prevalent Users over a 20 Year Period Using a Large Database
Abstract Number: 1161

Patient Preferences for Hydroxychloroquine in Systemic Lupus (SLE)
Abstract Number: 1162

Exploring Cannabis Use and Perspectives Among Psoriatic Disease Patients
Abstract Number: 1163

Patients’ Insights About Hydroxychloroquine, and Patient-Recommended Strategies to Target Nonadherence
Abstract Number: 1164

A Survey of Treatment Satisfaction with Intravenous Immunoglobulin Among Patients with Inflammatory Myositis
Abstract Number: 1165

“What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
Abstract Number: 1166

Marijuana Use Amongst Rheumatology Patients: It’s More Common Than Rheumatologists Believe

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].